Table 3.
Content of fatty acids in extracts from patients with chronic kidney disease (CKD) stage 5 and healthy controls serum mixes used for hepatocyte treatment in vitro. The data are presented as a fatty acid proportion (%). SFA—saturated fatty acids, MUFA—monounsaturated fatty acids, PUFA—polyunsaturated fatty acids.
| Item | Control | CKD Stage 5 |
|---|---|---|
| 14:0 | 1.02 | 1.33 |
| 16:0 | 22.72 | 26.84 |
| 18:0 | 7.99 | 6.46 |
| Other SFA | 1.56 | 1.10 |
| Total SFA | 32.27 | 35.73 |
| 14:1 | 0.04 | 0.09 |
| 16:1 | 1.74 | 3.29 |
| 18:1 | 23.59 | 29.59 |
| Other MUFA | 0.80 | 0.62 |
| Total MUFA | 26.17 | 33.85 |
| 18:3n-3 | 0.23 | 0.20 |
| 20:5n-3 | 0.94 | 0.66 |
| 22:6n-3 | 1.17 | 0.93 |
| Other n-3 PUFA | 0.37 | 0.30 |
| Total n-3 PUFA | 2.71 | 2.09 |
| 18:2n-6 | 30.03 | 22.76 |
| 20:4n-6 | 6.03 | 4.28 |
| Other n-6 PUFA | 1.5 | 0.93 |
| Total n-6 PUFA | 37.56 | 27.97 |